Therapeutic Antibodies – Multimedia

Antibodies are a rapidly growing, clinically successful type of biopharmaceutical, with more than 60 antibody-based drugs currently approved for use and marketed. This infographic highlights the different types of approved antibody drugs and gives an overview of antibody engineering and production.

This is the first in a three-part series of animations about therapeutic antibodies, providing viewers with an overview of antibody structure and function. The other two videos, will cover antibody 'mechanism of action' and antibody-drug conjugates

This list highlights 8 of the biggest milestones within the field of cancer research since the year 2000.

Professor Peter Johnson - Professor of Medical Oncology, University of Southampton and Chief Clinician for Cancer Research UK.

Drug developers are rapidly adopting Fc effector function reporter-based bioassays to measure antibody Fc functions such as ADCC and ADCP activity during the development of therapeutic antibodies. Here we show application of a suite of FcgR Reporter Bioassays to elucidate and characterize antibody MOA.

Delivering drugs to their site of action is a necessary feature of all medications. Different strategies are currently being employed to enable the targeted delivery of biotherapeutics.

Tristan Vaughan, MedImmune Ltd, UK speaking at Antibodies in Drug Discovery 2016

Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.

Receptor mediated internalization is a key mechanism of action (MOA) for antibody drug conjugates (ADCs). However, current methods of studying antibody internalization have several limitations including: 1) A multistep process not suitable for screening; 2) Low signal-to-background ratios; 3) Not suitable for kinetic measurements. We have developed a method that mitigates problems associated with traditional internalization assays.

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.